Screener / SEC EDGAR /CIK 0000886163 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Health care · Pharmaceuticals

Ligand Pharmaceuticals Inc LGND

Compare with peers Embed
Planned sales, announced before they happen

2 trading plans running, 33 Form 144 notices for $37.3M

10-Q, 10-K and Form 144

What LGND's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Mar 7, 2025 to Sep 30, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Andrew Reardon
Chief Legal Officer
Adopted 10b5-1 plan Sep 23, 2026 10-Q Oct 30, 2026
What the company wrote
On September 23, 2026, Andrew Reardon, Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. The trading arrangement is designed to remain in effect until March 15, 2027 and covers the sale of up to 10,000 shares of the Company’s common stock, together with such number of shares of the Company’s common stock issued upon settlement of certain stock awards held by Mr. Reardon, net of shares sold or withheld to satisfy applicable tax obligations.
John Kozarich
Chairman of the Board of Directors
Adopted 10b5-1 plan Aug 12, 2026 10-Q Oct 30, 2026
What the company wrote
On August 12, 2026, John Kozarich, Chairman of the Board of Directors, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. The trading arrangement is designed to remain in effect until September 30, 2027 and covers the sale of up to 12,000 shares of the Company’s common stock.
Andrew Reardon
Chief Legal Officer
Adopted 10b5-1 plan Nov 24, 2025 10-K Feb 27, 2026
What the company wrote
On November 24, 2025, Andrew Reardon, our Chief Legal Officer, adopted a 10b5-1 trading arrangement that is designed to be in effect until September 2, 2026 with respect to the sale of up to 30,000 shares of the Company’s common stock all of which underlie stock options held by Mr. Reardon. Through the date of this report, Mr. Reardon has not sold any shares under the plan.
Octavio Espinoza
Chief Financial Officer
Adopted 10b5-1 plan Nov 19, 2025 10-K Feb 27, 2026
What the company wrote
On November 19, 2025, Octavio Espinoza, our Chief Financial Officer, adopted a 10b5-1 trading arrangement that is designed to be in effect until July 31, 2026 with respect to the sale of up to 5,130 shares of the Company’s common stock all of which underlie stock options that number of shares of the Company’s common stock issued upon settlement of certain stock awards held by Mr. Espinoza minus any shares sold or withheld to cover the applicable tax payments. Through the date of this report, Mr. Espinoza has not sold any shares under the plan. Each of the aforementioned trading arrangements is intended to satisfy the affirmative defense of Rule 10b5-1(c).
John Kozarich
Director and Chairman of the Board
Adopted 10b5-1 plan Mar 7, 2025 10-Q May 9, 2025

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 12, 2026 KOZARICH JOHN W
Director
500 $162K
Nov 12, 2026 KOZARICH JOHN W
Director
500 $159K
Nov 12, 2026 MARTINE ZIMMERMANN
Director
2,000 $636K
Nov 10, 2026 Aryeh Jason
Director
3,000 $960K
Nov 4, 2026 Aryeh Jason
Director
282 $90K
Nov 2, 2026 Aryeh Jason
Director
700 $222K
Oct 30, 2026 JASON M ARYEH
Director
1,209 $385K
Oct 30, 2026 Aryeh Jason
Director
202 $65K
Sep 10, 2026 MARTINE ZIMMERMANN
Director
1,200 $342K
Sep 3, 2026 ANDREW REARDON
Officer
15,000 $4.3M
Aug 12, 2026 OCTAVIO ESPINOZA
Officer
31,641 $9.1M
Aug 12, 2026 Jason Haas
Director
7,138 $2.1M
Jul 1, 2026 ANDREW REARDON
Officer
10,000 $3.2M
Jun 16, 2026 STEPHEN L. SABBA
Director
2,145 $545K
Jun 12, 2026 JASON HAAS
Director
6,461 $1.7M
Jun 11, 2026 Aryeh Jason
Director
4,500 $1.1M
Jun 10, 2026 Aryeh Jason
Director
500 $125K
Jun 10, 2026 JOHN L LAMATTINA
Director
4,519 $1.1M
Jun 10, 2026 Aryeh Jason
Director
5,000 $1.2M
May 13, 2026 JOHN KOZARICH
Director
1,575 $352K
May 12, 2026 JOHN KOZARICH
Director
459 $103K
May 1, 2026 KOZARICH JOHN W
Director
467 $107K
Apr 1, 2026 KOZARICH JOHN W
Director
467 $95K
Mar 23, 2026 STEPHEN L. SABBA
Director
1,000 $208K
Mar 11, 2026 OCTAVIO ESPINOZA
Officer
3,057 $649K
Mar 6, 2026 JOHN L LAMATTINA
Director
2,161 $434K
Mar 4, 2026 ANDREW REARDON
Officer
20,000 $4.1M
Mar 4, 2026 OCTAVIO ESPINOZA
Officer
13,423 $2.7M
Mar 3, 2026 STEPHEN L. SABBA
Director
2,034 $410K
Feb 2, 2026 KOZARICH JOHN W
Director
467 $90K
Jan 2, 2026 KOZARICH JOHN W
Director
467 $88K
Dec 12, 2025 OCTAVIO ESPINOZA
Officer
1,804 $340K
Dec 1, 2025 KOZARICH JOHN W
Director
467 $93K
Show the other 25 notices

From the Form 144 XML filed with the SEC, since Dec 1, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LGND/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.